ETON — Eton Pharmaceuticals, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1710340 ·
Last close
$32.59
Market Cap
$892.72M
52W High
$35.66
52W Low
$16.14
ADV30
413,030
Next earnings
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 24,266,000 14,735,000 2,414,000 1,554,000 97,710,000 19,661,000 67,095,000
Dec 2025 21,281,000 13,100,000 2,464,000 1,483,000 92,114,000 25,942,000 65,960,000
Sep 2025 22,459,000 7,855,000 -1,363,000 -1,927,000 104,510,000 37,121,000 81,384,000
Jun 2025 18,928,000 11,924,000 -1,475,000 -2,585,000 101,676,000 25,379,000 77,715,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$10,524,000
Investing CF
$-333,000
Financing CF
$815,000
CapEx
$-8,181,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.18
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-112,494,000
Inventory
$15,419,000
Receivables
$11,757,000
ST Investments
EBIT TTM
$-844,000
Pretax Income TTM
$-4,558,000
Interest Exp TTM
$2,672,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$86,934,000
EBITDA
$11,085,000
Free Cash Flow
$2,438,625
Enterprise Value
$904,317,952
Total Cash
$19,661,000
Total Debt
$31,262,000
Shares Out
27,392,358
Trailing EPS
$-0.06
Book Value
$0.97
ROE
-5.4%
ROA
4.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 79,950,000 -844,000 -4,601,000 92,114,000 65,960,000 10,524,000
Dec 2024 39,011,000 -2,597,000 -3,823,000 76,123,000 51,695,000 969,000
Dec 2023 31,642,000 -1,192,000 -936,000 31,740,000 16,263,000 6,815,000
Dec 2022 21,251,000 -8,260,000 -9,021,000 25,030,000 11,952,000 4,821,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$1.88

Peers — same industry

TickerNameMarket CapLastDaily %
PHAR Pharming Group N.V. $889.88M $12.60
JANX Janux Therapeutics, Inc. $885.49M $14.52
PHAT Phathom Pharmaceuticals, Inc. $903.63M $11.33
SDGR Schrodinger, Inc. $871.90M $13.30
ANNX Annexon, Inc. $870.00M $5.31

News headlines (Yahoo Finance, 1h cache)

H.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth Strategy
2026-05-23 12:16 · Yahoo
Stock Market Leaders Respect The 21-Day Line. You Should Too.
2026-05-22 14:32 · Yahoo
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
2026-05-19 20:30 · Yahoo
Eton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen Next
2026-05-16 14:33 · Yahoo
Eton (ETON) Q1 2026 Earnings Call Transcript
2026-05-15 17:21 · Yahoo
Eton Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
2026-05-15 12:30 · Yahoo
Eton Pharmaceuticals Inc (ETON) Q1 2026 Earnings Call Highlights: Record Sales and Strategic ...
2026-05-15 05:02 · Yahoo
Eton Pharmaceuticals Q1 Earnings Call Highlights
2026-05-15 00:05 · Yahoo
Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates
2026-05-14 21:30 · Yahoo
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
2026-05-14 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.